Evidence map›Paper›PMID 32875127›Full record

ArticleClinical and translational radiation oncology2020

MRI detected extaprostatic extension (EPE) in prostate cancer: Do all T3a patients have the same outcomes?

A Gomez-Iturriaga, D Büchser, I San Miguel, M Marban, A Urresola, A Ezquerro, A Gil, F Suarez, A Gonzalez, E Mairata and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational radiation oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

A Gomez-IturriagaHospital Universitario Cruces/Biocruces Bizkaia Health Research Institute, Radiation Oncology, Barakaldo, Spain.
D BüchserHospital Universitario Cruces/Biocruces Bizkaia Health Research Institute, Radiation Oncology, Barakaldo, Spain.
I San MiguelHospital Universitario Cruces/Biocruces Bizkaia Health Research Institute, Radiation Oncology, Barakaldo, Spain.
M MarbanHospital Universitario Cruces/Biocruces Bizkaia Health Research Institute, Radiation Oncology, Barakaldo, Spain.
A UrresolaHospital Universitario Cruces/Biocruces Bizkaia Health Research Institute, Radiation Oncology, Barakaldo, Spain.
A EzquerroHospital Universitario Cruces/Biocruces Bizkaia Health Research Institute, Radiation Oncology, Barakaldo, Spain.
A GilHospital Universitario Cruces/Biocruces Bizkaia Health Research Institute, Radiation Oncology, Barakaldo, Spain.
F SuarezHospital Universitario Cruces/Biocruces Bizkaia Health Research Institute, Radiation Oncology, Barakaldo, Spain.
A GonzalezHospital Universitario Cruces/Biocruces Bizkaia Health Research Institute, Radiation Oncology, Barakaldo, Spain.
E MairataHospital Universitario Cruces/Biocruces Bizkaia Health Research Institute, Radiation Oncology, Barakaldo, Spain.
L Martinez-IndartHospital Universitario Cruces/Biocruces Health Research Institute, Clinical Epidemiology Unit, Barakaldo, Spain.
J CacicedoHospital Universitario Cruces/Biocruces Bizkaia Health Research Institute, Radiation Oncology, Barakaldo, Spain.
F CouñagoDepartment of Radiation Oncology, Hospital Universitario Quirón salud Madrid, 28223 Pozuelo de Alarcón, Madrid, Spain.
P MínguezHospital Universitario Cruces/Biocruces Bizkaia Health Research Institute, Radiation Oncology, Barakaldo, Spain.
F CasqueroHospital Universitario Cruces/Biocruces Bizkaia Health Research Institute, Radiation Oncology, Barakaldo, Spain.
BioCruces Health research Institute · ESHospital Universitario Quirónsalud Madrid · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MRI-detected T3a prostate cancer is a heterogeneous disease. This post-hoc analysis of a prospective trial found that patients with T3a disease presenting obliteration of the recto-prostatic angle, contact-asymmetry of neuro-vascular bundle and periprostatic fat invasion, may be at higher risk of biochemical failure and metastases.

Indexed as

Biochemical failureExtraprostatic extensionMetastasesMultiparametric MRIProstate cancerRadiotherapy

Identifiers

PMID32875127
PMCPMC7451735
OpenAlexW3049251485

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.